Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect data from patients by social media and self-report on the adverse events and outcomes happened with patients with extranodal natural killer/T-cell lymphoma, nasal type, who are treated outside of clinical trials in China.
Extranodal natural killer/T-cell lymphoma, nasal type, is a rare subtype of non-Hodgkin lymphoma with relatively high incidence in China. L-asparaginase based chemotherapy are widely used with Chinese patients and has been reported to improve overall response and prolonged the long-term survival in some clinical trials with very limited patients. However, most patients were treated out of clinical trials in China. Therefore the real incidence of adverse events and treatment outcomes are largely unknown. This study is designed to evaluate the incidence of adverse events and treatment outcomes by social media-based (www.house086.com, www.wechat.com) self-report from patients who are treated out of clinical trials.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| L-Asparaginase or or Pegaspargase containing chemotherapy | Combination Product | Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase. |
| Measure | Description | Time Frame |
|---|---|---|
| overall survival | The overall survial time of patients will be measured since the initiation of treatment to death of any reason. | 2-year |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-Related Adverse Events as Assessed by CTCAE v4.0 | Chemotherapy-related and radiotherapy-related toxicities and adverse events will be collected and graded by NCI CTCAE v4.0 criteria. | Day 1 of each course of chemotherapy and radiotherapy then every 3 months for 2 years |
| Progression free survival |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
All patients with the diagnosis of NK/TCL treated out of clinical trials are candidators for this study.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rong Tao, MD | Xinhua hospital, Shanghai Jiao Tong University of Medicine | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lymphoma House086 | Beijing | Beijing Municipality | 100010 | China | ||
| Xinhua Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D054391 | Lymphoma, Extranodal NK-T-Cell |
| ID | Term |
|---|---|
| D016399 | Lymphoma, T-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| D001215 | Asparaginase |
| ID | Term |
|---|---|
| D000581 | Amidohydrolases |
| D006867 | Hydrolases |
| D004798 | Enzymes |
| D045762 | Enzymes and Coenzymes |
Not provided
Not provided
Not provided
Not provided
Not provided
Progression free survival time is defined as the time from the initiation of treatment to the date on which disease "progresses" or the date on which the patient dies, from any cause. |
| 2-year |
| Shanghai |
| Shanghai Municipality |
| 200092 |
| China |
| D009369 |
| Neoplasms |